TMCnet News
Emerging Markets Consulting, LLC.: Emerging Markets Consulting, LLC. : Emerging Equity AlertsOrlando, FL, Aug 12, 2009 (M2 PRESSWIRE via COMTEX) -- Stocks gaining traction in today's trading are Helicos BioSciences Corporation, (NASDAQ:HLCS), Avanir Pharmaceuticals, (NASDAQ:AVNR), and RELM Wireless Corporation, (AMEX: RWC). Money flow and a positive chart pattern can be important indicators in the timing of a trade. To receive our complimentary newsletters please copy and paste http://www.emergingmarketsllc.com into your web browser. In the upper right hand corner of the homepage enter your email address and click sign up. You will receive a confirmation email. Click the link and your free subscription will be active. Do you Twitter? If so, check me out at http://twitter.com/MicroCapMaster! You can also visit my blog at http://www.emergingmarketsconsulting.blogspot.com/ Helicos BioSciences Corporation $1.29 up $0.57 (79.17%) Helicos BioSciences Corporation (NASDAQ: HLCS - News), a life science company focused on innovative genetic analysis technologies, yesterday announced the publication of a breakthrough study in which a Helicos Genetic Analysis System was used to sequence a human genome at the Stanford Institute for Stem Cell and Regenerative Medicine. The research article, now appearing in the on-line edition of Nature Biotechnology, demonstrates the power, accuracy and ease-of-use of the Helicos System. About Helicos BioSciences Corporation Helicos BioSciences Corporation, a life sciences company, focuses on genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets. The company's products are based on its proprietary True Single Molecule Sequencing technology, which enables the analysis of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. Its Helicos genetic analysis platform consists of HeliScope single molecule sequencer; HeliScope analysis engine, an image analysis computer tower; associated reagents, which are chemicals used in the sequencing process; and disposable supplies. The company's Helicos genetic analysis system is used for various applications in the areas of studying the human genome, disease association studies, cancer research, pharmaceutical research and development, infectious diseases, autoimmune conditions, clinical diagnostics, and agricultural research. Its customers include genome sequencing centers, biotechnology and pharmaceutical companies, and academic medical centers and research institutions in the United States and Canada. The company was formerly known as Newco LS6, Inc. and changed its name to Helicos BioSciences Corporation in November 2003. Helicos BioSciences Corporation was founded in 2003 and is headquartered in Cambridge, Massachusetts. Avanir Pharmaceuticals was trading at $3.39 up $1.20 (54.79%) Shares of Avanir Pharmaceuticals surged in premarket trading after the company said a new formula of its drug Zenvia met the main goal of a late-stage study. The drug is aimed at reducing emotional outbursts, including uncontrolled crying or laughing, as part of a disorder called pseudobulbar affect. The company's stock rose $1.66, or 76 percent, to $3.85 in premarket trading after closing at $2.19 during the regular trading session Monday. In the late-stage study, Zenvia reduced emotional outbursts by 47.2 percent, compared with placebo. That topped the goal of the study, which was a 36 percent reduction. Avanir expects to submit the data to the Food and Drug Administration in the first half of 2010. In 2007, the company started the additional late-stage study on a low-dose version of the drug following an agreement with the agency. In 2006, the FDA had asked for more information on the drug to consider it for approval. About Avanir Pharmaceuticals Avanir Pharmaceuticals, a pharmaceutical company, focuses on developing, acquiring, and commercializing therapeutic products for the treatment of chronic diseases primarily in the United States. The company's product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its lead product candidate Zenvia, a Phase III clinical development stage product for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The company's commercialized product, Abreva, an over-the-counter product for the treatment of cold sores, which is marketed by GlaxoSmithKline Consumer Healthcare in North America. Its inflammatory disease program, which targets macrophage migration inhibitory factor is partnered with Novartis International Pharmaceutical, Ltd. Avanir Pharmaceuticals was founded in 1988 and is headquartered in Aliso Viejo, California. RELM Wireless Corporation was trading at $2.72 up $0.71 (35.32%) RELM Wireless Corporation (NYSE: AMEX - RWC) today announced that it has been awarded an order totaling $1.8 million from the U.S. Department of Defense (DoD). This order is for the Company's new digital P25 KNG products and accessories. It is anticipated that the order will be largely fulfilled during the third quarter of 2009. About RELM Wireless Corporation RELM Wireless Corporation engages in the design, manufacture, and marketing of wireless communications products for government and public safety, and business and industrial markets in the United States and internationally. The company's products include two-way land mobile radios, repeaters, base stations, and related components and subsystems. It offers land-mobile radio equipment for professional radio users primarily in government and public safety applications, as well as P25 digital products under the BK Radio-brand; RELM-branded products that provide two-way communications for commercial and industrial concerns, such as hotels, construction firms, schools, and transportation services; and RELM/BK-branded products for land-mobile radio users. The company was founded in 1957 and is based in West Melbourne, Florida. About Emerging Markets Consulting, LLC Emerging Markets Consulting, LLC is an investor relations and consulting firm serving carefully selected micro cap and small cap clients. Services available include turnkey investor relations services, consulting, marketing and related services needed by publicly traded companies. EMC is unique in that they only work with companies after a stringent due diligence process and they also work with a limited number of clients in order to provide service that is exceptional. The above referenced companies are not clients of Emerging Markets and no compensation has been paid for the exposure provided by this report. Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited. Please remember to go to www.emergingmarketsllc.com and enter your email address to sign up for our free newsletter. Contact: Emerging Markets Consulting, LLC. Telephone - 321-206-6682 or email [email protected] CONTACT: Emerging Markets Consulting, LLC Tel: +1 321 206 6682 e-mail: [email protected] ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected]. |